Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 6/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.42 |
| ▸ | EGFR | P00533 | 8/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904064 | 0.92 | AAK1 (0.65) | AAK1BRAFTNNI3KEGFRERBB2 | |
| SCHEMBL9928291 | 0.86 | EGFR (0.53) | BRAFTNNI3KEGFRERBB2 | |
| SCHEMBL9928282 | 0.86 | EGFR (0.53) | BRAFTNNI3KEGFRERBB2LRRK2 | |
| SCHEMBL9928288 | 0.84 | EGFR (0.55) | BRAFTNNI3KEGFRERBB2LRRK2 | |
| SCHEMBL9897618 | 0.83 | AAK1 (0.47) | AAK1EGFRJAK3 | |
| SCHEMBL9928274 | 0.81 | BRAF (0.52) | AAK1BRAFTNNI3KEGFRERBB2 | |
| SCHEMBL9928293 | 0.81 | ERBB2 (0.44) | BRAFTNNI3KEGFRERBB2DRD2 | |
| SCHEMBL9928289 | 0.80 | AXL (0.39) | BRAFTNNI3KEGFRERBB2DRD2 | |
| SCHEMBL9928277 | 0.79 | BRAF (0.47) | AAK1BRAFTNNI3KEGFRERBB2 | |
| SCHEMBL9928290 | 0.79 | MERTK (0.39) | BRAFTNNI3KEGFRERBB2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | AAK1 709/4885BRAF 131/4885TNNI3K 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.